The influence of acute coronary syndrome on the levels of clopidogrel active metabolite and platelet inhibition in patients with and without CYP2C19 and ABCB1 gene polymorphisms

MLA

Tomasz Wójcik, et al. “The Influence of Acute Coronary Syndrome on the Levels of Clopidogrel Active Metabolite and Platelet Inhibition in Patients with and without CYP2C19 and ABCB1 Gene Polymorphisms.” Advances in Interventional Cardiology, vol. 17, no. 2, July 2021, pp. 179–86. EBSCOhost, https://doi.org/10.5114/aic.2021.106894.

APA

Tomasz Wójcik, Bożena Karolko, Jerzy Wiśniewski, Andrzej Mysiak, Krzysztof Ściborski, Grzegorz Onisk, Arleta Lebioda, Anna Jonkisz, & Marcin Protasiewicz. (2021). The influence of acute coronary syndrome on the levels of clopidogrel active metabolite and platelet inhibition in patients with and without CYP2C19 and ABCB1 gene polymorphisms. Advances in Interventional Cardiology, 17(2), 179–186. https://doi.org/10.5114/aic.2021.106894

Chicago

Tomasz Wójcik, Bożena Karolko, Jerzy Wiśniewski, Andrzej Mysiak, Krzysztof Ściborski, Grzegorz Onisk, Arleta Lebioda, Anna Jonkisz, and Marcin Protasiewicz. 2021. “The Influence of Acute Coronary Syndrome on the Levels of Clopidogrel Active Metabolite and Platelet Inhibition in Patients with and without CYP2C19 and ABCB1 Gene Polymorphisms.” Advances in Interventional Cardiology 17 (2): 179–86. doi:10.5114/aic.2021.106894.